RT Journal Article
SR Electronic
T1 Cancer immunotherapy does not increase the risk of death by COVID-19 in melanoma patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.19.20106971
DO 10.1101/2020.05.19.20106971
A1 Gonzalez-Cao, Maria
A1 Basa, Mónica Antoñanzas
A1 Puertolas, Teresa
A1 Muñoz, Eva
A1 Manzano, José Luis
A1 Carrera, Cristina
A1 Marquez-Rodas, Ivan
A1 Criado, Pilar Lopez
A1 Moreno, Juan Francisco Rodriguez
A1 Castaño, Almudena García
A1 Martín-Liberal, Juan
A1 Rodríguez-Jiménez, Pedro
A1 Puig, Susana
A1 Cerezuela, Pablo
A1 Feito Rodríguez, Marta
A1 Viqueira, Belén Rubio
A1 Crespo, Guillermo
A1 Fra, Pablo Luna
A1 Zamora, Cristina Aguayo
A1 de Miguel, Pablo Ayala
A1 Ochoa, Rosa Feltes
A1 Valles, Lara
A1 Drozdowskyj, Ana
A1 Soria, Ainara
A1 Maldonado Seral, Cayetana
A1 Fernández-Morales, Luis
A1 Rosell, Rafael
A1 Provencio, Mariano
A1 Berrocal, Alfonso
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/05/21/2020.05.19.20106971.abstract
AB Background Covid-19 pandemic by the new coronavirus SARS-Cov-2 has produced devastating effects on the health care system, affecting also cancer patient care. Data about COVID-19 infection in cancer patients are scarce, and they point out a higher risk of complications due to the viral infection in this population. Moreover, cancer treatments could increase viral complications, specially those treatments based on the use of immunotherapy with checkpoints antibodies. There are no clinical data about the safety of immune check point antibodies in cancer patients when they become infected by SARS-CoV-2. As checkpoint inhibitors, mainly anti PD-1 and anti CTLA-4 antibodies, are an effective treatment for most melanoma patients, avoiding their use during the pandemic could lead to a decrease in the chances of curing melanoma.Methods In Spain we have started a national registry of melanoma patients infected by SARS-Cov-2 since April 1st, 2020. A retrospective analysis of patients included in the Spanish registery has been performed weekly since the activation of the study. Interim analysis shows unexpected findings about cancer treatment safety in SARS-Cov-2 infected melanoma patients, so a rapid communication to the scientific community is mandatoryResults Fifty patients have been included as of May 17th, 2020. Median age is 69 years (range 6 to 94 years), 27 (54%) patients are males and 36 (70%) patients have stage IV melanoma. Twenty-two (44%) patients were on active anticancer treatment with anti PD-1 antibodies, 16 (32%) patients were on treatment with BRAF plus MEK inhibitors and 12 (24%) patients were not on active cancer treatment. COVID-19 episode has been resolved in 43 cases, including 30 (70%) patients cured, four (9%) patients that have died due to melanoma progression, and nine (21%) patients that have died from COVID-19. Mortality rates from COVID-19 according to melanoma treatment type were 16%, 15% and 36% for patients on immunotherapy, targeted drugs, and for those that were not undergoing active cancer treatment, respectively.Conclusion These preliminary findings show that the risk of death in those patients under going treatment with anti PD-1 antibodies does not exceed the global risk of death in this population. These results could be relevant in order to select melanoma therapy during the COVID-19 pandemicCompeting Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding has been receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDatabase and analysis is available for the Spanish Melanoma Group